Envista Holdings Corporation (NYSE:NVST) Receives Average Recommendation of “Hold” from Brokerages

Envista Holdings Corporation (NYSE:NVST) has earned an average rating of “Hold” from the sixteen ratings firms that are currently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating, five have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $21.5385.

Several equities research analysts recently weighed in on NVST shares. Barclays assumed coverage on shares of Envista in a report on Monday, December 8th. They issued an “overweight” rating and a $24.00 price objective for the company. Zacks Research cut shares of Envista from a “strong-buy” rating to a “hold” rating in a report on Monday, September 15th. Stifel Nicolaus set a $25.00 target price on Envista in a report on Thursday, October 30th. Weiss Ratings restated a “sell (d)” rating on shares of Envista in a research report on Monday, December 8th. Finally, Mizuho set a $19.00 price objective on Envista in a research note on Monday, November 3rd.

Envista Trading Down 0.8%

Envista stock opened at $21.96 on Monday. The firm has a 50-day moving average price of $20.17 and a two-hundred day moving average price of $20.14. The firm has a market capitalization of $3.61 billion, a price-to-earnings ratio of 244.04, a PEG ratio of 1.08 and a beta of 1.02. The company has a quick ratio of 2.02, a current ratio of 2.37 and a debt-to-equity ratio of 0.47. Envista has a 52-week low of $14.22 and a 52-week high of $22.68.

Envista (NYSE:NVST) last issued its quarterly earnings data on Wednesday, October 29th. The company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. The business had revenue of $669.90 million during the quarter, compared to analyst estimates of $639.49 million. Envista had a return on equity of 5.90% and a net margin of 0.58%.The business’s revenue for the quarter was up 11.5% compared to the same quarter last year. During the same period in the prior year, the company posted $0.12 EPS. Sell-side analysts expect that Envista will post 1 earnings per share for the current year.

Hedge Funds Weigh In On Envista

Several large investors have recently made changes to their positions in NVST. Alliancebernstein L.P. lifted its stake in Envista by 1,985.1% during the first quarter. Alliancebernstein L.P. now owns 4,550,789 shares of the company’s stock valued at $78,547,000 after purchasing an additional 4,332,541 shares during the last quarter. Holocene Advisors LP bought a new stake in shares of Envista during the 2nd quarter worth $43,936,000. Norges Bank acquired a new position in shares of Envista in the 2nd quarter worth $40,229,000. Dimensional Fund Advisors LP raised its position in shares of Envista by 24.0% during the first quarter. Dimensional Fund Advisors LP now owns 8,387,297 shares of the company’s stock worth $144,760,000 after purchasing an additional 1,625,206 shares during the period. Finally, Franklin Resources Inc. boosted its position in shares of Envista by 16.7% in the 2nd quarter. Franklin Resources Inc. now owns 8,956,572 shares of the company’s stock valued at $175,011,000 after purchasing an additional 1,284,767 shares during the period.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.